DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
DIV-AD
1 other identifier
observational
250
1 country
1
Brief Summary
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona. It will also examine how factors such as age, income, education, and health conditions may affect these levels. In addition, the study will identify barriers that may make it difficult to use these blood tests in primary care. The final goal is to help ensure that everyone in Barcelona has fair access to early prevention strategies for Alzheimer's disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2026
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 30, 2026
CompletedFirst Posted
Study publicly available on registry
April 13, 2026
CompletedStudy Start
First participant enrolled
April 27, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
April 27, 2027
Study Completion
Last participant's last visit for all outcomes
January 1, 2029
April 13, 2026
February 1, 2026
1 year
March 30, 2026
April 7, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Plasma levels of Alzheimer's disease blood-based biomarkers across ethnic groups
The contribution of sociodemographic factors, medical comorbidities, and biological variables to observed differences in levels of blood-based biomarkers will be assessed.
Through study completion, an average of 1 year
Secondary Outcomes (1)
Proportion of participants classified as low, intermediate, or high risk for AD pathology by plasma p-tau217 threshold, per ethnic group
Through study completion, an average of 1 year
Other Outcomes (2)
Validation of the RUDAS scale in a multi-ethnic primary care population
Single time-point assessment (cross-sectional)
Coded thematic categories from in-depth interviews on healthcare barriers, dementia stigma, and illness narratives
Year 1
Study Arms (5)
European
50 participants from any European country
South Asian
50 participants from Pakistan, India, Bangladesh
Filipinos
50 participants from Philippines
Latin America
50 participants from any country of South America
Maghrebi
50 participants from any country of the Magheb region (Morocco, Tunisia, Mauritania, Algeria, Libya)
Eligibility Criteria
The study will enroll 250 cognitively unimpaired adults aged 50-75 years, recruited from the patient registry of the Primary Care Team Raval Sud (EAP Raval Sud) in Barcelona, Spain. This primary care center is embedded in the Raval neighborhood of the Ciutat Vella district, one of the most ethnically diverse areas of Barcelona, characterized by a high proportion of foreign-born residents (over 63%)
You may qualify if:
- Cognitively Unimpaired individuals aged between 50 and 75 years at the time of signing the informed consent
- Individuals interested in participating, able to follow study procedures, and who understand that all the tests are carried out in a research context.
- Explicit desire to participate in the tests and procedures of the study, including: collection of study variables, cognitive and neurologic assessment, blood sampling.
- Signing the informed consent, agreeing not to receive the research results that will not be of no clinical interest for the participant.
You may not qualify if:
- Cognitive decline defined by CDR\>0.
- Individuals with cognitive complaints and who have sought for medical help for cognitive impairment at any time in their life
- Patients with relevant medical illnesses that may significantly interfere with the interpretation of results. This includes auditory and visual perception disorders, active oncological disease under treatment (localized tumors are excluded) and any condition that, in the investigator's opinion, may interfere with the correct performance/interpretation of the study procedures and/or with future permanence in the study.
- Major psychiatric disorders (according to the DSM-V manual) or diseases that affect cognitive abilities (major depressive episode, bipolar disorder, schizophrenia, etc).
- Acquired brain damage: history of head trauma with macroscopic parenchymal or non-axial lesion, large-vessel ischemic or hemorrhagic stroke, brain tumours and any other etiologies that can cause acquired brain damage (i.e., chemotherapy or brain radiotherapy).
- Parkinson's disease, epilepsy under treatment and with frequent seizures (\> 1/month) in the last year, multiple sclerosis or other neurodegenerative diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Universitat Pompeu Fabracollaborator
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundationlead
- Hospital del Mar Research Institute (IMIM)collaborator
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurinacollaborator
- Hospital del Marcollaborator
Study Sites (1)
BarcelonaBeta Brain Research Center - EAP Raval Sud
Barcelona, Spain
Biospecimen
Blood samples for the analysis of Alzheimer's disease biomarkers Blood samples for the extraction and analysis of DNA
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 30, 2026
First Posted
April 13, 2026
Study Start (Estimated)
April 27, 2026
Primary Completion (Estimated)
April 27, 2027
Study Completion (Estimated)
January 1, 2029
Last Updated
April 13, 2026
Record last verified: 2026-02